{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T05:13:04Z","timestamp":1740978784155,"version":"3.38.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013700","name":"National Comprehensive Cancer Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jtocrr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JTO Clinical and Research Reports"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jtocrr.2024.100757","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T23:06:19Z","timestamp":1730761579000},"page":"100757","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors"],"prefix":"10.1016","volume":"6","author":[{"given":"Nathaniel J.","family":"Myall","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer G.","family":"Whisenant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel W.","family":"Neal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wade T.","family":"Iams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen L.","family":"Reckamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sally","family":"York","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynne D.","family":"Berry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Shyr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leora","family":"Horn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather A.","family":"Wakelee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sukhmani K.","family":"Padda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtocrr.2024.100757_bib1","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/jnci\/dji055","article-title":"Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers","volume":"97","author":"Shigematsu","year":"2005","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jtocrr.2024.100757_bib2","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1158\/1078-0432.CCR-17-2289","article-title":"The impact of smoking and TP53 mutations in lung adenocarcinoma patients with targetable mutations-the lung cancer mutation consortium (LCMC2)","volume":"24","author":"Aisner","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtocrr.2024.100757_bib3","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtocrr.2024.100757_bib4","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtocrr.2024.100757_bib5","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002003","article-title":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","volume":"3","author":"Sequist","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtocrr.2024.100757_bib6","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR mutation and resistance of non-small-cell lung cancer to gefitinib","volume":"352","author":"Kobayashi","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtocrr.2024.100757_bib7","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtocrr.2024.100757_bib8","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtocrr.2024.100757_bib9","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1001\/jamaoncol.2018.2969","article-title":"Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib","volume":"4","author":"Oxnard","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtocrr.2024.100757_bib10","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/s41467-023-35962-x","article-title":"Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtocrr.2024.100757_bib11","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1158\/1078-0432.CCR-10-2662","article-title":"Phase I\/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib","volume":"17","author":"Janjigian","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtocrr.2024.100757_bib12","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41467-023-35961-y","article-title":"Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtocrr.2024.100757_bib13","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14768","article-title":"Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer","volume":"8","author":"Uchibori","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtocrr.2024.100757_bib14","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.jtho.2020.04.014","article-title":"Effective treatment of lung adenocarcinoma harboring EGFR-activating mutation, T790M, and cis-C797S triple mutations by brigatinib and cetuximab combination therapy","volume":"15","author":"Wang","year":"2020","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2024.100757_bib15","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1002\/cncr.10372","article-title":"Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy","volume":"94","author":"Herbst","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.jtocrr.2024.100757_bib16","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1097\/JTO.0b013e3181f0bee0","article-title":"Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy","volume":"5","author":"Neal","year":"2010","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2024.100757_bib17","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1038\/onc.2008.109","article-title":"BIBW2992, an irreversible EGFR\/HER2 inhibitor highly effective in preclinical lung cancer models","volume":"27","author":"Li","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.jtocrr.2024.100757_bib18","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtocrr.2024.100757_bib19","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1470-2045(15)00026-1","article-title":"Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2024.100757_bib20","first-page":"3000","article-title":"Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer","volume":"119","author":"Regales","year":"2009","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jtocrr.2024.100757_bib21","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1158\/2159-8290.CD-14-0326","article-title":"Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations","volume":"4","author":"Janjigian","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtocrr.2024.100757_bib22","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1158\/1078-0432.CCR-09-2425","article-title":"A\u00a0phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies","volume":"16","author":"Kuenen","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtocrr.2024.100757_bib23","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline, version 1.1","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtocrr.2024.100757_bib24","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jtho.2016.11.2236","article-title":"Risk of treatment-related toxicities from EGFR tyrosine kinase inhibitors: a meta-analysis of clinical trials of gefitinib, erlotinib, and afatinib in advanced EGFR-mutated non-small cell lung cancer","volume":"12","author":"Ding","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2024.100757_bib25","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.9014","article-title":"Osimertinib plus necitumumab in EGFR-mutant NSCLC: final results from an ETCTN California Cancer Consortium phase I study","volume":"40","author":"Riess","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtocrr.2024.100757_bib26","article-title":"Afatinib after progression on osimertinib in EGFR-mutated non-small cell lung cancer","volume":"30","author":"Aredo","year":"2022","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.jtocrr.2024.100757_bib27","article-title":"Pilot study of dacomitinib for patients with metastatic EGFR-mutant lung cancers with disease progression after initial treatment with osimertinib","volume":"5","author":"Choudhury","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jtocrr.2024.100757_bib28","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1200\/JCO.20.01149","article-title":"Randomized trial of afatinib plus cetuximab versus afatinib alone for first-line treatment of EGFR-mutant non-small-cell lung cancer: final results from SWOG S1403","volume":"38","author":"Goldberg","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtocrr.2024.100757_bib29","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1158\/1078-0432.CCR-20-4604","article-title":"First-line afatinib plus cetuximab for EGFR-mutant non-small cell lung cancer: results from the randomized Phase II IFCT-1503 ACE-lung study","volume":"27","author":"Cortot","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"suppl 15","key":"10.1016\/j.jtocrr.2024.100757_bib30","article-title":"Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-na\u00efve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response","volume":"39","author":"Bauml","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtocrr.2024.100757_bib31","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1158\/2159-8290.CD-21-0715","article-title":"Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer","volume":"12","author":"Janne","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtocrr.2024.100757_bib32","doi-asserted-by":"crossref","first-page":"8249","DOI":"10.1021\/jm500973a","article-title":"Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor","volume":"57","author":"Finlay","year":"2014","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.jtocrr.2024.100757_bib33","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1200\/JCO.2007.14.0111","article-title":"Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy","volume":"26","author":"Hirsch","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtocrr.2024.100757_bib34","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1470-2045(11)70189-9","article-title":"Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study","volume":"12","author":"O\u2019Byrne","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2024.100757_bib35","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(09)60569-9","article-title":"Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial","volume":"373","author":"Pirker","year":"2009","journal-title":"Lancet"}],"container-title":["JTO Clinical and Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364324001279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364324001279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T04:04:56Z","timestamp":1740888296000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666364324001279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2666364324001279"],"URL":"https:\/\/doi.org\/10.1016\/j.jtocrr.2024.100757","relation":{},"ISSN":["2666-3643"],"issn-type":[{"type":"print","value":"2666-3643"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors","name":"articletitle","label":"Article Title"},{"value":"JTO Clinical and Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtocrr.2024.100757","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"100757"}}